CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection

BIOLOGICAL2 trials

Sponsors

Immunomic Therapeutics, Inc.

Conditions

Allergic Rhinoconjunctivitis

Phase 1

A Safety and Immunogenicity Phase I Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid

CompletedNCT01707069

Immunomic Therapeutics, Inc.Allergic Rhinoconjunctivitis

Start: 2012-10-31End: 2013-06-30Updated: 2014-05-22

A Safety and Immunogenicity Phase IB Study of CryJ2-DNA-Lysosomal Associated Membrane Protein (CryJ2 -DNA-LAMP) Plasmid Assessing the Long Term Safety of Previously Treated Subjects

CompletedNCT01966224

Immunomic Therapeutics, Inc.Allergic Rhinoconjunctivitis

Start: 2013-09-30End: 2013-12-31Updated: 2014-04-30